Relationship between the expression of NM23 and E-cadherin and the efficacy of neoadjuvant chemotherapy in breast cancer#br#
YANG Lei1 YANG Hongwei1 CHEN Maoshan1 MU Dewu1 CHENG Xiaoming2
1.Department of Breast and Thyroid Surgery, Suining Central Hospital, Sichuan Province, Suining 629000, China;
2.Department of Thyroid and Breast Surgery, Affiliated Hospital of Zunyi Medical University, Guizhou Province, Zunyi 563000, China
Abstract：Objective To investigate the relationship between the expression of NM23 and E-cadherin and the efficacy of neoadjuvant chemotherapy (NCT) in breast cancer. Methods The clinical data of 87 patients with invasive breast cancer who received NCT were collected from Department of Thyroid and Breast Surgery, Affiliated Hospital of Zunyi Medical University from October 2014 to October 2017. According to the effect of NCT, they were divided into effective group (63 cases) and ineffective group (24 cases). The expression of NM23 and E-cadherin in NCT precancerous tissues of 87 patients with invasive breast cancer was detected by immunohistochemical method, and the relationship between the expression of NM23 and E-cadherin and the effect of NCT was analyzed. Results The proportion of NM23 positive, TNM stage Ⅲ, and human epidermal growth factor receptor-2 positive in ineffective group were lower than those in effective group, and the proportion of E-cadherin positive was higher than that in effective group, the differences were statistically significant (P ＜ 0.05). Multivariate analysis showed that positive E-cadherin expression was an independent risk factor for NCT inefficacy in breast cancer (OR ＞ 1, P ＜ 0.05), while positive NM23 expression and TNM stage Ⅲ were protective factors (OR ＜ 1, P ＜ 0.05). Conclusion The expression levels of NM23 and E-cadherin in breast cancer tissues are significantly correlated with the effect of NCT in breast cancer, which has certain reference value for evaluating the effect of breast cancer patients after NCT.
杨磊1 杨宏伟1 陈茂山1 牟德武1 程晓明2. 乳腺癌组织中NM23及上皮钙黏素的表达与新辅助化疗效果的关系[J]. 中国医药导报, 2022, 19(8): 93-96.
YANG Lei1 YANG Hongwei1 CHEN Maoshan1 MU Dewu1 CHENG Xiaoming2. Relationship between the expression of NM23 and E-cadherin and the efficacy of neoadjuvant chemotherapy in breast cancer#br#. 中国医药导报, 2022, 19(8): 93-96.
[1] Desantis C，Ma J，Bryan L，et al. Breast cancer statistics，2013 [J]. CA Cancer J Clin，2014，64（1）：52-62.
[2] Ferlay J，Soerjomataram I，Dikshit R，et al. Cancer incidence and mortality worldwide：sources，methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer，2015， 136（5）：E359-E386.
[3] 杨彬，邢君，王睿，等.多学科模式在乳腺癌诊治中的实践及新进展[J].中国医药导报，2019，16（26）：54-56，63.
[4] 中国抗癌协会乳腺癌专业委员会.中国晚期乳腺癌临床诊疗专家共识（2018版）[J].中华肿瘤杂志，2018，40（9）：703-713.
[5] Apuri S. Neoadjuvant and Adjuvant Therapies for Breast Cancer [J]. South Med J，2017，110（10）：638-642.
[6] Duran E，Cardenas JM，Reina MA，et al. Loss of Nm23 is associated with a more favorable tumor microenvironment in patients with breast cancer [J]. Histol Histopathol，2015， 30（3）：345-352.
[7] Van Roy F. Beyond E-cadherin：roles of other cadherin superfamily members in cancer [J]. Nat Rev Cancer，2014， 14（2）：121-134.
[8] Nie M，Qin Y，Zhu J，et al. Correlation between ultrasonic features and expression levels of C-erbB-2，VEGF and nm23 in breast cancer [J]. Oncol Lett，2018，16（2）：1701-1707.
[9] Von Minckwitz G，Untch M，Blohmer JU，et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes [J]. J Clin Oncol，2012，30（15）：1796-1804.
[10] Symmans WF，Peintinger F，Hatzis C，et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy [J]. J Clin Oncol，2007，25（28）：4414-4422.
[11] Weber JJ，Jochelson MS，Eaton A，et al. MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer [J]. J Am Coll Surg，2017，225（6）：740-746.
[12] 徐晶晶，邱岑，郑建明.乳腺癌组织中ALDH1、BRCA1、nm23蛋白表达变化及意义[J].山东医药，2020，60（28）：50-53.
[13] 李俊，李春英.CD44V4和nm23在三阴性乳腺癌中的表达及其相关性[J].中国医药导报，2019，16（29）：100-103.
[14] Ferguson AW，Flatow U，Macdonald NJ，et al. Increased sensitivity to cisplatin by nm23-transfected tumor cell lines [J]. Cancer Res，1996，56（13）：2931-2935.
[15] Lizuka N，Miyamoto K，Tangoku A，et al. Downregulation of intracellular nm23-H1 prevents cisplatin-induced DNA damage in oesophageal cancer cells：possible association with Na（+），K（+）-ATPase [J]. Br J Cancer，2000，83（9）：1209-1215.
[16] Wang LS，Chow KC，Lien YC，et al. Prognostic significance of nm23-H1 expression in esophageal squamous cell carcinoma [J]. Eur J Cardiothorac Surg，2004，26（2）：419-424.
[17] 赵伟志，赵薇，杨小兵，等.浸润性乳腺癌组织HER2与Ki67联合表达与蒽环类化疗药物的疗效及预后相关[J].南京医科大学学报：自然科学版，2021，41（6）：873-878， 898.
[18] He G，Kuang J，Khokhar AR，et al. The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum（Ⅳ）analog [J]. Gynecol Oncol，2011，122（2）：402-409.
[19] Caligo MA，Cipollini G，Fiore L，et al. NM23 gene expression correlates with cell growth rate and S-phase [J]. Int J Cancer，1995，60（6）：837-842.
[20] Lombardi D. Commentary：nm23，a metastasis suppressor gene with a tumor suppressor gene aptitude？[J]. J Bioenerg Biomembr，2006，38（3/4）：177-180.
[21] Wang L，Li Z，Wang C，et al. E-cadherin decreased human breast cancer cells sensitivity to staurosporine by up-regulating Bcl-2 expression [J]. Arch Biochem Biophys，2009，481（1）：116-122.
[22] Lu L，Tang D，Wang L，et al. Gambogic acid inhibits TNF-alpha-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-kappaB signaling pathways [J]. Acta Pharmacol Sin，2012，33（4）：531-541.
[23] Yu Y，Wang L，Tang W，et al. RNA interference-mediated knockdown of Notch-1 inhibits migration and invasion，down-regulates matrix metalloproteinases and suppresses NF-kappaB signaling pathway in trophoblast cells [J]. Acta Histochem，2014，116（5）：911-919.
[24] Blanco D，Vicent S，Elizegi E，et al. Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis [J]. Lab Invest，2004，84（8）：999-1012.
[25] Martz CA，Ottina KA，Singleton KR，et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance [J]. Sci Signal，2014，7（357）：ra121.
[26] Meng RD，Shelton CC，Li YM，et al. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity [J]. Cancer Res，2009， 69（2）：573-582.
京公网安备 11010502046598号